POMC, proopiomelanocortin, 5443

N. diseases: 873; N. variants: 39
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Alpha melanocyte stimulating hormone (α-MSH) enhances melanogenesis in melanoma malignum by binding to melanocortin-1 receptors (MC1-R). 28625749 2017
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE αMSH peptide sequences, evaluated for conjugation to the PEG-Cy5-C' dot nanoparticles, bound to MC1-R with high affinity and targeted melanoma in syngenetic and xenografted melanoma mouse models. 29058865 2018
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Alpha-MSH, a proopiomelanocortin (POMC)-derived peptide, is known to be produced in the pituitary, the skin, and melanoma tumors and to possess many biological effects, mainly on melanocyte pigmentation and growth. 9572472 1998
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE An (18)F-labeled linear alpha-MSH peptide ((18)F-FB-Ac-Nle-Asp-His-d-Phe-Arg-Trp-Gly-Lys-NH(2) [NAPamide]) shows promising melanoma imaging properties but with only moderate tumor uptake and retention. 19837749 2009
CUI: C0025202
Disease: melanoma
melanoma
0.400 Therapeutic disease CTD_human Because the apoptotic cells were detected mainly in regions distant from blood vessels, it was hypothesized that POMC therapy might render melanoma cells vulnerable to hypoxic insult. 24412703 2014
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Furthermore, the relevance of alpha-melanocyte-stimulating hormone-mediated signaling for the induction of cytotoxicity was assessed in CD8(+) T cells from melanoma patients with functional and nonfunctional melanocortin-1 receptors. 20126537 2010
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Herein, we sought to establish a simple preparation method for an <sup>18</sup>F-labeled α-MSH analog using Al<sup>18</sup>F, and we examined its potential for the early detection of melanoma. 31297699 2019
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE However, melanoma cells synthesize and release alpha-melanocyte stimulating hormone (alphaMSH, the ligand for MC1R), therefore MC1R variants could alter the autocrine effects of alphaMSH on melanoma cell behaviour, thereby affecting early melanoma development and progression via non-pigmentary mechanisms. 12439754 2002
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE In contrast to melanoma cells, nevus cells in serum-free medium require the presence of alpha-melanocyte-stimulating hormone, which enhanced intracellular levels of cyclic adenosine monophosphate. 8440904 1993
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease LHGDN In CRH positive melanomas, seven out of nine cases (78%) of primary melanoma, and 7 out of 12 cases (58%) of MetM showed colocalization of CRH and POMC peptides. 11936276 2002
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE In melanocytes and melanoma cells alpha-melanocyte stimulating hormone (alpha-MSH), via the cAMP pathway, elicits a large array of biological responses that control melanocyte differentiation and influence melanoma development or susceptibility. 15983061 2005
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE In summary, systemic POMC therapy suppresses melanoma growth via induction of melanogenic differentiation and angiogenesis blockade, thereby demonstrating its potential as a novel treatment modality for melanoma. 21126174 2011
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE In this study, we aim to design and evaluate αMSH derivatives that enable radiolabeling with <sup>18</sup>F for PET imaging of melanoma. 29714486 2018
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Linear and cyclic analogues of the α-melanocyte stimulating hormone (α-MSH) targeting the human melanocortin receptor 1 (MC1R) are of pharmacological interest for detecting and treating melanoma. 28714883 2017
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Linking αMSH with PPARγ in B16-F10 melanoma. 22863076 2013
CUI: C0025202
Disease: melanoma
melanoma
0.400 GeneticVariation disease BEFREE MC1R, a G-protein coupled receptor with high affinity for alpha-melanocyte stimulating hormone (αMSH), modulates pigment production in melanocytes from many species and is associated with human melanoma risk. 29316344 2018
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Our previous studies have indicated that POMC gene delivery inhibited the progression and metastasis of B16-F10 melanoma via the α- melanocyte-stimulating hormone/melanortin-1 receptor (MC-1R) pathway. 22147647 2012
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Radiolabeled α-melanocyte-stimulating hormone (α-MSH) derivatives have a high potential for diagnosis and treatment of melanoma, because of high specificity and binding affinity to the melanocortin-1 receptor (MC1R). 30912594 2019
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Radiolabeled linear or cyclic analogs of α-MSH have a great potential as diagnostic or therapeutic tools for the management of malignant melanoma. 28491052 2017
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Radionuclide Targeting: α-Melanocyte-stimulating hormone (α-MSH) is the most prominent peptide for targeting of melanoma tumors via the G protein-coupled melanocortin-1 receptor that is (over-)expressed by melanoma cells and melanocytes. 28578648 2017
CUI: C0025202
Disease: melanoma
melanoma
0.400 AlteredExpression disease BEFREE Syndecan-2 expression was enhanced by fibroblast growth factor-2, which is known to stimulate melanoma cell migration; however, alpha-melanocyte-stimulating hormone decreased syndecan-2 expression and melanoma cell migration and invasion in a melanin synthesis-independent manner. 19641225 2009
CUI: C0025202
Disease: melanoma
melanoma
0.400 AlteredExpression disease BEFREE The human melanocortin-1 (MC1) receptor was stably expressed in the amelanotic mouse melanoma cell clone B16-G4F which does not express its own (mouse) MC1 receptor and hence is unresponsive to alpha melanocyte stimulating hormone (alpha MSH). 8856498 1996
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE The importance of the MC1R in reducing UV-induced genotoxicity in melanocytes led us to design small peptide analogs of the physiological MC1R agonist α-melanocortin (α-melanocyte stimulating hormone; α-MSH) for the goal of utilizing them for melanoma chemoprevention. 25017567 2014
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE These results highlight the potential of using radiolabeled αMSH analogues in clinical applications for molecular imaging and radionuclide therapy of melanoma. 29182034 2018
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE This may be a reason for concern in patients with malignant melanoma (MM): Melanocortin receptors bind to ACTH and the different isoforms of MSH. 31272482 2019